Exelixis Inc
EXEL39.150USD
+0.600+1.56%
Handelsschluss 04/30, 16:00（ET）Kurse um 15 Minuten verzögert
11.03BMarktkapitalisierung
21.16KGV TTM
mehr Informationen über Exelixis Inc Unternehmen
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Unternehmensinformationen
Unternehmens-codeEXEL
Name des UnternehmensExelixis Inc
IPO-datumApr 11, 2000
Gegründet am1994
CEODr. Michael M. Morrissey, Ph.D.
Anzahl der mitarbeiter1147
WertpapierartOrdinary Share
GeschäftsjahresendeApr 11
Addresse1851 Harbor Bay Parkway
StadtALAMEDA
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl94502
Telefon16508377000
Websitehttps://www.exelixis.com/
Unternehmens-codeEXEL
IPO-datumApr 11, 2000
Gegründet am1994
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Michael M. Morrissey, Ph.D.
Dr. Michael M. Morrissey, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.37M
+33.08%
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
1.26M
+0.15%
Mr. Jeffrey J. Hessekiel, J.D.
Mr. Jeffrey J. Hessekiel, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
469.73K
+48.81%
Dr. Dana T. Aftab, Ph.D.
Dr. Dana T. Aftab, Ph.D.
Executive Vice President - Discovery and Translational Research, Chief Scientific Officer
Executive Vice President - Discovery and Translational Research, Chief Scientific Officer
391.52K
+51.34%
Mr. Patrick Joseph Haley
Mr. Patrick Joseph Haley
Executive Vice President - Commercial
Executive Vice President - Commercial
347.62K
+75.36%
Mr. Jack L. Wyszomierski
Mr. Jack L. Wyszomierski
Independent Director
Independent Director
337.77K
+2.73%
Dr. Amy C. Peterson, M.D.
Dr. Amy C. Peterson, M.D.
Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer
Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer
192.16K
+486.28%
Dr. George H. Poste, Ph.D.
Dr. George H. Poste, Ph.D.
Independent Director
Independent Director
150.18K
+1.27%
Dr. Maria C. Freire, Ph.D.
Dr. Maria C. Freire, Ph.D.
Independent Director
Independent Director
72.17K
+2.67%
Ms. Julie Anne Smith
Ms. Julie Anne Smith
Independent Director
Independent Director
763.00
-92.92%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Michael M. Morrissey, Ph.D.
Dr. Michael M. Morrissey, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.37M
+33.08%
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
1.26M
+0.15%
Mr. Jeffrey J. Hessekiel, J.D.
Mr. Jeffrey J. Hessekiel, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
469.73K
+48.81%
Dr. Dana T. Aftab, Ph.D.
Dr. Dana T. Aftab, Ph.D.
Executive Vice President - Discovery and Translational Research, Chief Scientific Officer
Executive Vice President - Discovery and Translational Research, Chief Scientific Officer
391.52K
+51.34%
Mr. Patrick Joseph Haley
Mr. Patrick Joseph Haley
Executive Vice President - Commercial
Executive Vice President - Commercial
347.62K
+75.36%
Mr. Jack L. Wyszomierski
Mr. Jack L. Wyszomierski
Independent Director
Independent Director
337.77K
+2.73%
Umsatzaufteilung
Währung: USDUpdate-Zeit: Sun, Apr 6
Währung: USDUpdate-Zeit: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
CABOMETYX
1.80B
82.92%
License revenues
349.24M
16.10%
COMETRIQ
11.16M
0.51%
Collaboration services revenues
10.06M
0.46%
Nach RegionUSD
Name
Umsatz
Anteil
U.S
1.82B
84.06%
Europe
318.63M
14.69%
Japan
27.08M
1.25%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
CABOMETYX
1.80B
82.92%
License revenues
349.24M
16.10%
COMETRIQ
11.16M
0.51%
Collaboration services revenues
10.06M
0.46%
Aktionäre
Update-Zeit: Fri, Feb 21
Update-Zeit: Fri, Feb 21
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
The Vanguard Group, Inc.
10.66%
BlackRock Institutional Trust Company, N.A.
9.69%
Farallon Capital Management, L.L.C.
8.51%
Renaissance Technologies LLC
5.55%
State Street Global Advisors (US)
4.14%
Other
61.45%
Aktionärsstatistik
Aktionäre
Anteil
The Vanguard Group, Inc.
10.66%
BlackRock Institutional Trust Company, N.A.
9.69%
Farallon Capital Management, L.L.C.
8.51%
Renaissance Technologies LLC
5.55%
State Street Global Advisors (US)
4.14%
Other
61.45%
Art
Aktionäre
Anteil
Investment Advisor/Hedge Fund
35.93%
Investment Advisor
32.99%
Hedge Fund
18.79%
Pension Fund
2.94%
Individual Investor
2.28%
Research Firm
1.77%
Sovereign Wealth Fund
1.22%
Bank and Trust
0.48%
Family Office
0.10%
Other
3.49%
Institutionelle Beteiligung
Update-Zeit: Mon, Jan 20
Update-Zeit: Mon, Jan 20
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
997
267.27M
96.95%
-4.60M
2024Q4
992
262.76M
93.66%
-11.36M
2024Q3
924
259.58M
90.96%
-10.18M
2024Q2
908
255.61M
87.75%
-22.29M
2024Q1
905
264.69M
87.26%
-20.82M
2023Q4
882
270.85M
87.07%
-16.64M
2023Q3
847
278.02M
87.32%
-18.15M
2023Q2
833
285.95M
87.85%
-21.34M
2023Q1
841
294.75M
90.97%
-14.08M
2022Q4
839
295.50M
91.62%
-5.46M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
29.37M
10.49%
+120.47K
+0.41%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
26.71M
9.54%
-308.83K
-1.14%
Dec 31, 2024
Farallon Capital Management, L.L.C.
23.44M
8.37%
--
--
Mar 05, 2025
Renaissance Technologies LLC
15.30M
5.47%
-64.05K
-0.42%
Dec 31, 2024
State Street Global Advisors (US)
11.41M
4.08%
-31.73K
-0.28%
Dec 31, 2024
LSV Asset Management
8.17M
2.92%
+67.47K
+0.83%
Dec 31, 2024
Fuller & Thaler Asset Management Inc.
7.63M
2.73%
+708.31K
+10.23%
Dec 31, 2024
Geode Capital Management, L.L.C.
5.16M
1.84%
-5.12K
-0.10%
Dec 31, 2024
Dimensional Fund Advisors, L.P.
5.10M
1.82%
-153.57K
-2.92%
Dec 31, 2024
AQR Capital Management, LLC
3.97M
1.42%
+810.86K
+25.69%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: Sun, Apr 6
Update-Zeit: Sun, Apr 6
Name
Anteil
iShares Genomics Immunology and Healthcare ETF
4.81%
Tema Oncology ETF
4.2%
Alger Russell Innovation ETF
3.77%
First Trust NYSE Arca Biotechnology Index Fund
3.34%
Burney US Factor Rotation ETF
3.31%
Invesco Biotechnology & Genome ETF
2.89%
ERShares Entrepreneurs ETF
2.66%
First Trust Health Care Alphadex Fund
2.51%
Range Cancer Immunotherapy ETF
2.48%
Adaptiv Select ETF
2.04%
Mehr Anzeigen
iShares Genomics Immunology and Healthcare ETF
Anteil4.81%
Tema Oncology ETF
Anteil4.2%
Alger Russell Innovation ETF
Anteil3.77%
First Trust NYSE Arca Biotechnology Index Fund
Anteil3.34%
Burney US Factor Rotation ETF
Anteil3.31%
Invesco Biotechnology & Genome ETF
Anteil2.89%
ERShares Entrepreneurs ETF
Anteil2.66%
First Trust Health Care Alphadex Fund
Anteil2.51%
Range Cancer Immunotherapy ETF
Anteil2.48%
Adaptiv Select ETF
Anteil2.04%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten